Author/Authors :
Shahsiah, Reza tehran university of medical sciences tums - Department of Pathology and Laboratory Medicine, تهران, ايران , Azmoudeh Ardalan, Farid tehran university of medical sciences tums - Department of Pathology and Laboratory Medicine, تهران, ايران , Nassiri Toosi, Mohsen tehran university of medical sciences tums - Department of Gastroenterology and Hepatology, تهران, ايران , Jahanzad, Issa tehran university of medical sciences tums - School of Medicine - Dept of Pathology, تهران, ايران , Abdollahi, Alireza tehran university of medical sciences tums - Department of Pathology and Laboratory Medicine, تهران, ايران
Abstract :
The National Institute of Health’s (NIH)workshop, “Management of Hepatitis B,”has proposed the HBV DNA level of 105 copies/ml (20,000 IU/mL) as the point of differentiationof chronic hepatitis B from the inactive carrier state(1). Optimal management of chronic hepatitis Brequires the use of PCR assays to establish a baselineHBV DNA level and then the use of PCR assayantiviral therapy for monitoring the response andviral rebound associated with viral resistance (2).
